| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition Disorders | 15 | 2017 | 181 | 2.800 |
Why?
|
| Neuropsychological Tests | 17 | 2019 | 237 | 2.660 |
Why?
|
| Veterans | 8 | 2015 | 66 | 2.290 |
Why?
|
| Alcoholism | 14 | 2024 | 116 | 2.190 |
Why?
|
| Stress, Psychological | 13 | 2019 | 209 | 2.120 |
Why?
|
| Military Personnel | 6 | 2015 | 45 | 2.090 |
Why?
|
| Brain Injuries | 6 | 2015 | 49 | 1.810 |
Why?
|
| Hydrocortisone | 11 | 2019 | 88 | 1.550 |
Why?
|
| Family Health | 11 | 2019 | 71 | 1.550 |
Why?
|
| Blood Platelets | 16 | 2020 | 203 | 1.340 |
Why?
|
| Male | 73 | 2024 | 13008 | 1.200 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2017 | 57 | 1.160 |
Why?
|
| Spinal Cord Injuries | 3 | 2013 | 55 | 1.140 |
Why?
|
| Female | 69 | 2024 | 14625 | 1.080 |
Why?
|
| Adult | 48 | 2024 | 7494 | 1.050 |
Why?
|
| Young Adult | 25 | 2024 | 2628 | 1.000 |
Why?
|
| Adolescent | 26 | 2024 | 2990 | 0.940 |
Why?
|
| Humans | 81 | 2024 | 27125 | 0.920 |
Why?
|
| Life Change Events | 3 | 2015 | 33 | 0.900 |
Why?
|
| Middle Aged | 35 | 2019 | 6901 | 0.830 |
Why?
|
| Substance-Related Disorders | 7 | 2024 | 175 | 0.810 |
Why?
|
| Multiple Sclerosis | 2 | 2013 | 81 | 0.800 |
Why?
|
| Cognition | 7 | 2017 | 298 | 0.780 |
Why?
|
| Aged | 29 | 2019 | 5217 | 0.690 |
Why?
|
| Adult Survivors of Child Abuse | 4 | 2018 | 18 | 0.670 |
Why?
|
| Risk Factors | 21 | 2020 | 2036 | 0.670 |
Why?
|
| Benchmarking | 1 | 2019 | 29 | 0.660 |
Why?
|
| Circadian Rhythm | 4 | 2019 | 76 | 0.650 |
Why?
|
| Arousal | 2 | 2018 | 38 | 0.640 |
Why?
|
| Brain Concussion | 2 | 2016 | 43 | 0.640 |
Why?
|
| Aged, 80 and over | 16 | 2019 | 1935 | 0.630 |
Why?
|
| Child Abuse | 3 | 2019 | 88 | 0.620 |
Why?
|
| Ischemic Attack, Transient | 5 | 2020 | 25 | 0.610 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 117 | 0.590 |
Why?
|
| Naltrexone | 3 | 2018 | 19 | 0.590 |
Why?
|
| Independent Living | 1 | 2017 | 14 | 0.570 |
Why?
|
| Stroke | 5 | 2020 | 241 | 0.550 |
Why?
|
| Disability Evaluation | 2 | 2015 | 54 | 0.540 |
Why?
|
| Computers, Handheld | 1 | 2016 | 12 | 0.530 |
Why?
|
| Impulsive Behavior | 3 | 2015 | 13 | 0.520 |
Why?
|
| Mass Screening | 1 | 2017 | 148 | 0.520 |
Why?
|
| Outpatients | 2 | 2013 | 42 | 0.500 |
Why?
|
| Wheelchairs | 1 | 2015 | 5 | 0.500 |
Why?
|
| Disabled Persons | 1 | 2015 | 18 | 0.490 |
Why?
|
| Mobility Limitation | 1 | 2015 | 14 | 0.490 |
Why?
|
| Sex Characteristics | 6 | 2015 | 163 | 0.490 |
Why?
|
| Pressure Ulcer | 2 | 2013 | 5 | 0.480 |
Why?
|
| Retrospective Studies | 8 | 2015 | 2461 | 0.460 |
Why?
|
| Caffeine | 7 | 2010 | 39 | 0.460 |
Why?
|
| 4-Aminopyridine | 1 | 2013 | 3 | 0.440 |
Why?
|
| Potassium Channel Blockers | 1 | 2013 | 10 | 0.440 |
Why?
|
| Gait | 1 | 2013 | 58 | 0.430 |
Why?
|
| Oklahoma | 10 | 2015 | 976 | 0.420 |
Why?
|
| Dementia | 1 | 2014 | 89 | 0.410 |
Why?
|
| Motor Activity | 1 | 2013 | 145 | 0.410 |
Why?
|
| Age Factors | 6 | 2015 | 721 | 0.400 |
Why?
|
| Warfare | 1 | 2012 | 9 | 0.400 |
Why?
|
| Affect | 5 | 2015 | 82 | 0.400 |
Why?
|
| Health Status | 1 | 2013 | 145 | 0.400 |
Why?
|
| Walking | 1 | 2013 | 130 | 0.390 |
Why?
|
| Individuality | 1 | 2011 | 19 | 0.390 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 54 | 0.370 |
Why?
|
| Platelet Activation | 7 | 2011 | 54 | 0.370 |
Why?
|
| Stress, Physiological | 1 | 2011 | 90 | 0.370 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2009 | 6 | 0.330 |
Why?
|
| Sensitivity and Specificity | 6 | 2017 | 509 | 0.330 |
Why?
|
| Quality of Life | 1 | 2013 | 464 | 0.320 |
Why?
|
| Rest | 1 | 2010 | 94 | 0.320 |
Why?
|
| Genetic Testing | 1 | 2009 | 64 | 0.320 |
Why?
|
| Retinal Diseases | 1 | 2009 | 45 | 0.320 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2019 | 10 | 0.310 |
Why?
|
| Psychometrics | 2 | 2019 | 117 | 0.300 |
Why?
|
| Tacrolimus Binding Proteins | 2 | 2019 | 7 | 0.290 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 751 | 0.290 |
Why?
|
| Narcotic Antagonists | 3 | 2018 | 31 | 0.280 |
Why?
|
| Memory, Short-Term | 2 | 2019 | 62 | 0.280 |
Why?
|
| Saliva | 6 | 2019 | 94 | 0.280 |
Why?
|
| Heart Rate | 5 | 2019 | 375 | 0.280 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 353 | 0.270 |
Why?
|
| Gene-Environment Interaction | 2 | 2017 | 12 | 0.270 |
Why?
|
| Alzheimer Disease | 4 | 2011 | 209 | 0.270 |
Why?
|
| Reaction Time | 3 | 2019 | 94 | 0.260 |
Why?
|
| Time Factors | 7 | 2019 | 1572 | 0.260 |
Why?
|
| Nervous System Diseases | 3 | 2017 | 39 | 0.250 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 447 | 0.250 |
Why?
|
| Reference Values | 3 | 2016 | 199 | 0.250 |
Why?
|
| Double-Blind Method | 9 | 2018 | 405 | 0.240 |
Why?
|
| Child | 4 | 2019 | 2164 | 0.240 |
Why?
|
| Copper | 3 | 2011 | 44 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2017 | 544 | 0.240 |
Why?
|
| Case-Control Studies | 7 | 2024 | 706 | 0.230 |
Why?
|
| Leukocytes | 1 | 2024 | 69 | 0.230 |
Why?
|
| Carotid Stenosis | 2 | 2014 | 25 | 0.230 |
Why?
|
| United States | 5 | 2017 | 2062 | 0.220 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2017 | 93 | 0.220 |
Why?
|
| Sex Factors | 3 | 2015 | 451 | 0.210 |
Why?
|
| Genotype | 5 | 2019 | 444 | 0.200 |
Why?
|
| Temperament | 4 | 2017 | 11 | 0.200 |
Why?
|
| Blood Pressure | 4 | 2010 | 351 | 0.200 |
Why?
|
| Delay Discounting | 2 | 2018 | 6 | 0.200 |
Why?
|
| Phenotype | 2 | 2017 | 665 | 0.190 |
Why?
|
| Amyloid beta-Protein Precursor | 4 | 2011 | 31 | 0.190 |
Why?
|
| Self Report | 2 | 2012 | 116 | 0.190 |
Why?
|
| Polymorphism, Genetic | 2 | 2019 | 163 | 0.180 |
Why?
|
| Parkinson Disease | 2 | 2012 | 38 | 0.170 |
Why?
|
| Ceruloplasmin | 3 | 2009 | 8 | 0.170 |
Why?
|
| Stroke, Lacunar | 1 | 2020 | 3 | 0.170 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2019 | 58 | 0.170 |
Why?
|
| Prevalence | 2 | 2012 | 475 | 0.170 |
Why?
|
| Platelet Count | 4 | 2015 | 112 | 0.170 |
Why?
|
| Hypertension | 3 | 2012 | 305 | 0.170 |
Why?
|
| Amnesia | 2 | 2011 | 9 | 0.160 |
Why?
|
| ROC Curve | 2 | 2017 | 137 | 0.160 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2012 | 19 | 0.160 |
Why?
|
| Pituitary-Adrenal System | 2 | 2012 | 20 | 0.160 |
Why?
|
| Ranibizumab | 1 | 2019 | 2 | 0.160 |
Why?
|
| Socioeconomic Factors | 3 | 2017 | 240 | 0.160 |
Why?
|
| Contraceptive Agents | 1 | 2019 | 8 | 0.160 |
Why?
|
| Choroidal Neovascularization | 1 | 2019 | 11 | 0.160 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2018 | 4 | 0.160 |
Why?
|
| Blindness | 1 | 2019 | 34 | 0.160 |
Why?
|
| Choroid | 1 | 2019 | 20 | 0.160 |
Why?
|
| Cerebral Hemorrhage | 2 | 2010 | 90 | 0.160 |
Why?
|
| Mental Disorders | 2 | 2017 | 104 | 0.150 |
Why?
|
| Retinal Vessels | 1 | 2019 | 71 | 0.150 |
Why?
|
| Visual Acuity | 1 | 2019 | 106 | 0.150 |
Why?
|
| Analysis of Variance | 2 | 2017 | 388 | 0.150 |
Why?
|
| Linear Models | 1 | 2018 | 202 | 0.150 |
Why?
|
| Tomography, Optical Coherence | 1 | 2019 | 89 | 0.150 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2017 | 8 | 0.140 |
Why?
|
| Cross-Over Studies | 7 | 2018 | 132 | 0.130 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 48 | 0.130 |
Why?
|
| Logistic Models | 1 | 2017 | 398 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 2 | 2006 | 30 | 0.130 |
Why?
|
| Age of Onset | 2 | 2013 | 69 | 0.130 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2015 | 7 | 0.120 |
Why?
|
| Hospitals, Veterans | 1 | 2015 | 22 | 0.120 |
Why?
|
| Receptors, Opioid, mu | 1 | 2015 | 22 | 0.120 |
Why?
|
| Chronic Disease | 2 | 2013 | 265 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2014 | 190 | 0.120 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 49 | 0.120 |
Why?
|
| Personality | 1 | 2015 | 24 | 0.120 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 218 | 0.120 |
Why?
|
| Hemodynamics | 2 | 2006 | 220 | 0.120 |
Why?
|
| Carotid Artery, Internal | 1 | 2014 | 19 | 0.120 |
Why?
|
| Asymptomatic Diseases | 1 | 2014 | 17 | 0.120 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 6 | 0.120 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 37 | 0.110 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 57 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2014 | 46 | 0.110 |
Why?
|
| Law Enforcement | 1 | 2013 | 6 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2019 | 399 | 0.110 |
Why?
|
| Antisocial Personality Disorder | 2 | 2011 | 12 | 0.110 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 39 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 106 | 0.110 |
Why?
|
| Thrombin | 5 | 2017 | 68 | 0.110 |
Why?
|
| Cause of Death | 1 | 2013 | 66 | 0.110 |
Why?
|
| Drug Tolerance | 4 | 2005 | 37 | 0.110 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 472 | 0.110 |
Why?
|
| Muscle Strength | 1 | 2015 | 228 | 0.110 |
Why?
|
| Demography | 1 | 2013 | 91 | 0.110 |
Why?
|
| Employment | 1 | 2013 | 45 | 0.100 |
Why?
|
| Stroop Test | 1 | 2012 | 8 | 0.100 |
Why?
|
| Mars | 1 | 2012 | 5 | 0.100 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2013 | 54 | 0.100 |
Why?
|
| Exercise Test | 1 | 2013 | 248 | 0.100 |
Why?
|
| Fatigue | 1 | 2012 | 63 | 0.100 |
Why?
|
| Afghan Campaign 2001- | 1 | 2012 | 11 | 0.100 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2012 | 11 | 0.100 |
Why?
|
| Psychological Techniques | 1 | 2011 | 4 | 0.100 |
Why?
|
| Time | 1 | 2011 | 16 | 0.100 |
Why?
|
| Abdominal Pain | 1 | 2012 | 34 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2019 | 2283 | 0.100 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 168 | 0.090 |
Why?
|
| Biomarkers | 2 | 2012 | 736 | 0.090 |
Why?
|
| Colonoscopy | 1 | 2012 | 58 | 0.090 |
Why?
|
| Social Class | 1 | 2011 | 78 | 0.090 |
Why?
|
| Vitamin B 12 Deficiency | 2 | 2009 | 9 | 0.090 |
Why?
|
| Reward | 1 | 2011 | 45 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 932 | 0.090 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 36 | 0.090 |
Why?
|
| Collagen | 4 | 2017 | 147 | 0.090 |
Why?
|
| Memory | 2 | 2012 | 71 | 0.090 |
Why?
|
| Diabetic Angiopathies | 1 | 2011 | 48 | 0.090 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 100 | 0.090 |
Why?
|
| Alcoholics | 1 | 2009 | 2 | 0.080 |
Why?
|
| Medical Audit | 1 | 2009 | 15 | 0.080 |
Why?
|
| Comprehension | 1 | 2009 | 17 | 0.080 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2009 | 21 | 0.080 |
Why?
|
| Frontotemporal Dementia | 1 | 2009 | 4 | 0.080 |
Why?
|
| Microarray Analysis | 1 | 2009 | 59 | 0.080 |
Why?
|
| Pilot Projects | 4 | 2015 | 397 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 927 | 0.080 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 163 | 0.080 |
Why?
|
| Gastrectomy | 1 | 2009 | 19 | 0.080 |
Why?
|
| Personality Inventory | 3 | 2015 | 26 | 0.080 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 8 | 0.080 |
Why?
|
| Brain | 1 | 2014 | 707 | 0.080 |
Why?
|
| Potassium | 1 | 2008 | 41 | 0.080 |
Why?
|
| Databases as Topic | 1 | 2008 | 21 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 33 | 0.080 |
Why?
|
| Reference Standards | 1 | 2008 | 54 | 0.080 |
Why?
|
| Brain Infarction | 1 | 2008 | 10 | 0.070 |
Why?
|
| Blood Coagulation Factors | 1 | 2008 | 31 | 0.070 |
Why?
|
| Disease Progression | 3 | 2019 | 457 | 0.070 |
Why?
|
| Neurodegenerative Diseases | 1 | 2007 | 21 | 0.070 |
Why?
|
| Brain Ischemia | 1 | 2008 | 82 | 0.070 |
Why?
|
| Kidney | 1 | 2008 | 275 | 0.070 |
Why?
|
| Aging | 1 | 2014 | 959 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2019 | 1223 | 0.070 |
Why?
|
| Eating | 1 | 2006 | 70 | 0.060 |
Why?
|
| Wakefulness | 1 | 2005 | 23 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 986 | 0.060 |
Why?
|
| Patient Selection | 1 | 2006 | 143 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2005 | 34 | 0.060 |
Why?
|
| Speech | 2 | 2019 | 12 | 0.060 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2015 | 26 | 0.060 |
Why?
|
| Leukocyte Count | 1 | 2024 | 25 | 0.060 |
Why?
|
| Serotonin Uptake Inhibitors | 2 | 2019 | 26 | 0.060 |
Why?
|
| Recurrence | 2 | 2020 | 316 | 0.060 |
Why?
|
| Decision Making | 1 | 2006 | 169 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2009 | 606 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 204 | 0.060 |
Why?
|
| Neutrophils | 1 | 2024 | 179 | 0.050 |
Why?
|
| Monocytes | 1 | 2024 | 132 | 0.050 |
Why?
|
| Animals | 2 | 2014 | 10063 | 0.050 |
Why?
|
| Psychomotor Performance | 2 | 2012 | 72 | 0.050 |
Why?
|
| Exercise | 1 | 2006 | 469 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2013 | 231 | 0.050 |
Why?
|
| Prognosis | 2 | 2017 | 762 | 0.050 |
Why?
|
| Random Allocation | 2 | 2015 | 148 | 0.050 |
Why?
|
| Risk-Taking | 2 | 2014 | 58 | 0.040 |
Why?
|
| Smoking | 2 | 2019 | 466 | 0.040 |
Why?
|
| Inflammation | 1 | 2024 | 605 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2014 | 285 | 0.040 |
Why?
|
| Fundus Oculi | 1 | 2019 | 15 | 0.040 |
Why?
|
| Fluorescein Angiography | 1 | 2019 | 16 | 0.040 |
Why?
|
| Intravitreal Injections | 1 | 2019 | 33 | 0.040 |
Why?
|
| Alleles | 1 | 2019 | 347 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 104 | 0.040 |
Why?
|
| Aspirin | 1 | 2019 | 122 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 177 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 50 | 0.040 |
Why?
|
| Surface Properties | 2 | 2008 | 132 | 0.030 |
Why?
|
| Mathematical Concepts | 1 | 2015 | 10 | 0.030 |
Why?
|
| Social Perception | 1 | 2015 | 23 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2017 | 594 | 0.030 |
Why?
|
| Hematologic Tests | 1 | 2014 | 7 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2014 | 24 | 0.030 |
Why?
|
| Models, Psychological | 1 | 2015 | 80 | 0.030 |
Why?
|
| Vascular Resistance | 2 | 2005 | 50 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 591 | 0.030 |
Why?
|
| Mood Disorders | 1 | 2014 | 24 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 189 | 0.030 |
Why?
|
| Weapons | 1 | 2013 | 1 | 0.030 |
Why?
|
| Conducted Energy Weapon Injuries | 1 | 2013 | 1 | 0.030 |
Why?
|
| Escape Reaction | 1 | 2013 | 4 | 0.030 |
Why?
|
| Electroshock | 1 | 2013 | 6 | 0.030 |
Why?
|
| Bites and Stings | 1 | 2013 | 6 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 217 | 0.030 |
Why?
|
| Irritants | 1 | 2013 | 7 | 0.030 |
Why?
|
| Violence | 1 | 2013 | 31 | 0.030 |
Why?
|
| Running | 1 | 2013 | 39 | 0.030 |
Why?
|
| Aerosols | 1 | 2013 | 41 | 0.030 |
Why?
|
| Dogs | 1 | 2013 | 504 | 0.030 |
Why?
|
| Depression | 1 | 2015 | 211 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 2012 | 10 | 0.030 |
Why?
|
| Actigraphy | 1 | 2012 | 22 | 0.030 |
Why?
|
| Sleep Deprivation | 1 | 2012 | 28 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 16 | 0.030 |
Why?
|
| Phototherapy | 1 | 2012 | 26 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 35 | 0.030 |
Why?
|
| Sleep | 1 | 2012 | 101 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 864 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2012 | 37 | 0.020 |
Why?
|
| Temperance | 1 | 2011 | 5 | 0.020 |
Why?
|
| Breath Tests | 1 | 2011 | 14 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2011 | 25 | 0.020 |
Why?
|
| Platelet Adhesiveness | 1 | 2011 | 6 | 0.020 |
Why?
|
| Coffee | 1 | 2010 | 5 | 0.020 |
Why?
|
| Premenopause | 1 | 2010 | 20 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2011 | 253 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2011 | 116 | 0.020 |
Why?
|
| Postmenopause | 1 | 2010 | 83 | 0.020 |
Why?
|
| Hyperkalemia | 1 | 2008 | 8 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2008 | 20 | 0.020 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2008 | 3 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 48 | 0.020 |
Why?
|
| Signal Detection, Psychological | 1 | 2008 | 8 | 0.020 |
Why?
|
| Models, Structural | 1 | 2007 | 13 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2008 | 28 | 0.020 |
Why?
|
| Vitamin B 12 | 1 | 2007 | 6 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2009 | 220 | 0.020 |
Why?
|
| Comorbidity | 1 | 2008 | 251 | 0.020 |
Why?
|
| Incidence | 1 | 2008 | 553 | 0.020 |
Why?
|
| Cardiography, Impedance | 1 | 2006 | 7 | 0.020 |
Why?
|
| Menstrual Cycle | 1 | 2006 | 23 | 0.020 |
Why?
|
| Gambling | 1 | 2006 | 9 | 0.020 |
Why?
|
| Behavior | 1 | 2006 | 14 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2006 | 21 | 0.020 |
Why?
|
| Telephone | 1 | 2006 | 25 | 0.020 |
Why?
|
| Crotalid Venoms | 1 | 2006 | 4 | 0.020 |
Why?
|
| Adrenal Cortex | 1 | 2005 | 13 | 0.020 |
Why?
|
| Education | 1 | 2006 | 33 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2008 | 213 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 56 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2006 | 118 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2006 | 36 | 0.020 |
Why?
|
| Secretory Rate | 1 | 2005 | 5 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 108 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2005 | 93 | 0.020 |
Why?
|
| Capsules | 1 | 2005 | 7 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 45 | 0.020 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2005 | 1 | 0.020 |
Why?
|
| Research Design | 1 | 2006 | 173 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2006 | 506 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 665 | 0.010 |
Why?
|